Compare Gold Fields Limited (GFI) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Philip Morris International Inc. — how do they compare? Gold Fields Limited trades at $36.7 (market cap $31.26B), while Philip Morris International Inc. trades at $200.48 (market cap $300.33B). The key difference: Philip Morris International Inc. is far larger — about 9.6× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Philip Morris International Inc. for 85 Days on average.
| GFI | PM | |
|---|---|---|
Market Cap | $31.26B | $300.33B |
Volume | 3,397,922 | 3,935,700 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $61.52 | $200.50 |
52-Week Low | $31.25 | $144.33 |
Typical Hold Time | 49 Days | 85 Days |
Enterprise Value | $31.87B | $343.44B |
Dividend Yield | 6.14% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.86, down 0.86% with bearish technical signals but strong fundamentals including 40.76% net margin and 58.38% ROE. Recent earnings show mixed results with one beat and three misses against expectations. The company's proposed $27 billion takeover of Northern Star was rejected, creating near-term uncertainty while highlighting growth ambitions. Operating cash flow surged to $3.77 billion in 2025, supporting robust shareholder returns.
GFI presents a value opportunity with low P/E of 7.14 and 44% upside to consensus target of $52.75, though recent acquisition volatility and earnings misses warrant caution. The stock's bearish technical posture contrasts with strong cash generation and analyst support (8 Buy, 10 Hold ratings), creating potential for recovery as standalone operations deliver growth.
Philip Morris International (PM) trades at $200.5, up 5.3% over 24 hours, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The company shows robust fundamentals with 2025 revenue of $40.65B and net income of $11.35B, supported by a 67.48% gross margin. Recent news highlights expansion of smoke-free products like ZYN and IQOS, now over 40% of revenue, driving growth amid industry shifts.
Outlook is positive with analyst consensus at Buy (68%) and a $212.17 price target, though elevated P/E of 26.46 and regulatory risks in tobacco remain concerns. Earnings growth and smoke-free product adoption are key catalysts, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
